Should Lilly Stock Before April 10 Be on Your Radar?
As April 10 approaches, investors debate whether Lilly stock is a buy. This guide breaks down catalysts, valuation, a...
This tag page gathers 4 Pharmaceuticals articles covering stock moves, earnings previews, and dip-buys to help you evaluate pharma equities and manage risk.
13 articlesAs April 10 approaches, investors debate whether Lilly stock is a buy. This guide breaks down catalysts, valuation, a...
In March 2026, the drug stock landscape blends steady demand with ongoing innovation. This article highlights three c...
Federal regulators are pulling nearly 90,000 bottles of children's ibuprofen from shelves after reports of foreign ma...
Pfizer has been a market mover, but recent shifts in demand and patent timelines raise concerns. This guide breaks do...
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Novo Nordisk faces intense pressure in the fast-growing obesity treatment space. This article dives into whether this...
Pharmaceutical tariffs could quietly raise out-of-pocket drug costs and slow medical innovation. This guide explains ...
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
When a blue-chip pharma stock falls 25%, many investors wonder if it's time to buy. This guide breaks down how to ass...
As Bausch Health prepares its Q4 2025 results, investors want clarity on margins, debt, and the pipeline. This guide ...
If you’re seeking a single, enduring reason to own Lilly stock, this article lays it out. You’ll learn how a durable ...